中國藥科大學

劉建平,1982年畢業(yè)于中國藥科大學藥學專業(yè)，現(xiàn)為中國藥科大學藥劑研究所所長、藥劑教研室副主任，藥劑學博士、教授、博士生導師。1999年赴新西蘭Otago大學藥學院進修。

兼任國家食品藥品監(jiān)督管理局保健品審評專家、農(nóng)業(yè)部獸藥審評專家、江蘇省藥劑專業(yè)委員會副主任、江蘇省藥品保健品制劑審評專家、江蘇省九三學社醫(yī)藥委員會委員等職。

研究方向：生物功能性藥物載體，緩控釋制劑、經(jīng)皮給藥系統(tǒng)、中藥新劑型

主要研究內(nèi)容和成果：利用血漿高密度脂蛋白逆轉(zhuǎn)運膽固醇，具有抗動脈粥樣硬化的性質(zhì)和作用，重組高密度脂蛋白載藥系統(tǒng)，達到載體與藥物的協(xié)同治療作用，獲2項國家自然科學基金項目資助；針對中藥多成分體內(nèi)過程差異較大，不利于發(fā)揮協(xié)同作用的問題，對中藥多成分體內(nèi)過程進行藥動學與藥效學的二次調(diào)控與改造，獲1項國家自然科學基金項目資助。主持科技部“十一五”重大專項、國家中醫(yī)藥管理局項目、江蘇省“六大人才”高峰項目、江蘇省自然科學基金、江蘇省社會發(fā)展基金等項目項目，負責或參與科技部“十五”國家科技攻關(guān)、“十一五”國家科技支撐計劃、新西蘭國際合作項目、江蘇省高新技術(shù)招標項目、江蘇省科技基礎設施建設計劃-科技公共服務平臺項目、江蘇省中醫(yī)藥管理局項目以及企業(yè)合作開發(fā)項目等共25項。

通過江蘇省科技廳成果鑒定三項，獲2004年南京市科技進步獎三等獎、2011國家人口和計生委優(yōu)秀科技成果一等獎，申請發(fā)明專利27項，已授權(quán)9項。發(fā)表論文129篇（其中SCI42篇、EI收載2篇）。

近3年發(fā)表的代表性論文（以下均為通訊作者）

1.Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation [J]. Journal of Controlled Release, 2015, 23(10): 161-169.(SCI，7.705)

2.Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein[J]. Pharmaceutical Research, Published online：04 June 2015.(SCI，3.952)

3.Tanshinone IIA loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation[J]. European Journal of Pharmaceutical Sciences, 2015, 76(2015): 156–164.(SCI，3.35)

4.Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug [J]. Pharmaceutical research, 2015, 32(4): 1451-1461. (SCI，3.952)

5.Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473 (1–2), 528–535. (SCI，3.785)

6.Hyaluronic acid-decorated reconstitude high density lipoprotein targeting atherosclerotic lesion [J]. Biomaterials, 2014, 35(27): 8002–8014. (SCI，8.312)

7.Arachidonic Acid-modified Lovastatin Discoidal Reconstituted High Density Lipoprotein Markedly Decrease the Drug Leakage during the Remodeling Behaviors Induced by Lecithin Cholesterol  Acyltransferase. Pharmaceutical Research, 2014, 31(7): 1689-1709. ( SCI， 3.952)

8.Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins, Biomaterials, 2013, 34(1):306-319. (SCI， 7.604)

9.Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug–phospholipids complex technique. European journal of pharmaceutics and biopharmaceutics, 2013,83(1):76-86. (SCI，3.826)

10.Release Behavior of Tanshinone IIA Sustained-Release Pellets Based on Crack Formation Theory. Journal of pharmaceutical sciences, 2012,101(8):2811-2820. (SCI，3.055)

11.Preparation, Characterizations, and In Vitro Metabolic Processes of Paclitaxel-Loaded Discoidal Recombinant High-Density Lipoproteins. Journal of pharmaceutical science, 2012,101(8):2900-2908. (SCI，3.055)

12.Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2012,80:426-432. (SCI，4.269)

聯(lián)系方式：025-83271293（O）,13951923397,jianpingliu1293@163.com